Characterization of protein therapeutics by mass spectrometry: recent developments and future directions

Guodong Chen; Bethanne M Warrack; Angela K Goodenough; Hui Wei; David B Wang-Iverson; Adrienne A Tymiak

doi:10.1016/j.drudis.2010.11.003

Characterization of protein therapeutics by mass spectrometry: recent developments and future directions

Drug Discov Today. 2011 Jan;16(1-2):58-64. doi: 10.1016/j.drudis.2010.11.003. Epub 2010 Nov 18.

Authors

Guodong Chen¹, Bethanne M Warrack, Angela K Goodenough, Hui Wei, David B Wang-Iverson, Adrienne A Tymiak

Affiliation

¹ Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543, USA. [email protected]

PMID: 21093608
DOI: 10.1016/j.drudis.2010.11.003

Abstract

Mass spectrometry (MS) has become a powerful technology in the discovery and development of protein therapeutics in the biopharmaceutical industry. This review article describes recent developments and future trends in the characterization of protein therapeutics using MS. We discuss top-down MS for the characterization of protein modifications, hydrogen/deuterium exchange MS and ion mobility MS methods for higher order protein structure studies. Quantitative analysis of protein therapeutics (in vivo) by MS as an orthogonal approach to immunoassay for pharmacokinetics studies will also be illustrated.

Publication types

Review

MeSH terms

Drug Discovery / methods*
Drug Discovery / trends
Forecasting
Humans
Mass Spectrometry / methods*
Mass Spectrometry / trends
Proteins / chemistry*
Proteins / pharmacokinetics
Proteins / therapeutic use*

Substances

Proteins